Literature DB >> 8596148

Small changes in outpatients lupus activity are better detected by clinical instruments than by laboratory tests.

P R Fortin1, M Abrahamowicz, D Danoff.   

Abstract

OBJECTIVE: To evaluate and compare responsiveness of laboratory and clinical measures over 4 months in outpatient systemic lupus erythematosus (SLE).
METHODS: We studied 23 patients with SLE at monthly intervals during 4 mo and collected demographic data, prednisone dose, global patient and physician assessment of disease activity on 10 cm visual analog scales (VAS), scores on 3 clinical measures of lupus disease activity [SLE disease activity index (SLEDAI), SLE activity measure (SLAM), lupus activity index (LAI)], and results of 5 routine laboratory tests [erythrocyte sedimentation rate (ESR), anti-dsDNA, C3, C4, circulating immune complexes]. We calculated correlations between a particular measure and our gold standard (physician's VAS) for individual patients and pooled this information using a novel application of the meta-analytic approach.
RESULTS: The range of disease activity by patient and physician VAS varied from inactive to moderately active> Change in patient global assessment and all 3 clinical measures showed significant positive correlations with change in physician VAS (p < 0.05). Change in ESR, anti-dsDNA, or level of C3, C4, or circulating immune complexes did not correlate with change in physician VAS.
CONCLUSION: Clinical measures of disease activity in SLE are more responsive to small changes than traditional laboratory tests. All 3 clinical measures appeared to perform equally well. At least one SLE disease activity measure should be used in SLE trials. The new analytic method will likely be of value in similar evaluations of responsiveness in other diseases.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8596148

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  3 in total

Review 1.  The use of laboratory tests in the diagnosis of SLE.

Authors:  W Egner
Journal:  J Clin Pathol       Date:  2000-06       Impact factor: 3.411

Review 2.  The validity and utility of the Cutaneous Disease Area and Severity Index (CDASI) as a clinical outcome instrument in dermatomyositis: A comprehensive review.

Authors:  S Ahmed; K L Chen; V P Werth
Journal:  Semin Arthritis Rheum       Date:  2020-01-11       Impact factor: 5.532

3.  Comparison of the reliability and validity of outcome instruments for cutaneous dermatomyositis.

Authors:  R Q Klein; C A Bangert; M Costner; M K Connolly; A Tanikawa; J Okawa; M Rose; S S Fakharzadeh; D Fiorentino; L A Lee; R D Sontheimer; L Taylor; A B Troxel; V P Werth
Journal:  Br J Dermatol       Date:  2008-07-04       Impact factor: 9.302

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.